Equities Analysts Issue Forecasts for AVTX Q3 Earnings

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for Avalo Therapeutics in a research note issued on Friday, August 7th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.58) per share for the quarter, down from their prior estimate of ($0.37). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($2.58) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.76) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.62) EPS and FY2027 earnings at ($2.41) EPS.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25).

A number of other equities analysts also recently commented on the stock. Guggenheim set a $48.00 target price on shares of Avalo Therapeutics and gave the stock a “buy” rating in a research note on Friday. Wall Street Zen cut Avalo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Mizuho lifted their price target on Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Bank of America began coverage on Avalo Therapeutics in a report on Friday, June 12th. They set a “buy” rating and a $35.00 price target for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Avalo Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $45.10.

Avalo Therapeutics Trading Up 7.9%

Shares of AVTX opened at $19.77 on Tuesday. Avalo Therapeutics has a twelve month low of $8.29 and a twelve month high of $24.27. The firm’s fifty day simple moving average is $17.34 and its 200-day simple moving average is $16.33. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -4.52 and a beta of 0.80.

Insider Activity

In other news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider owned 51,776 shares in the company, valued at approximately $931,968. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Orbimed Advisors LLC lifted its stake in Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after buying an additional 382,300 shares during the last quarter. Affinity Asset Advisors LLC grew its position in shares of Avalo Therapeutics by 27.6% during the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after acquiring an additional 289,786 shares during the last quarter. Nantahala Capital Management LLC grew its position in shares of Avalo Therapeutics by 24.1% during the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after acquiring an additional 240,000 shares during the last quarter. Caligan Partners LP increased its holdings in shares of Avalo Therapeutics by 5.8% in the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock valued at $16,009,000 after acquiring an additional 48,200 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Avalo Therapeutics in the 3rd quarter valued at $10,390,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

More Avalo Therapeutics News

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $30 price target, implying potential upside from recent trading levels. Bank of America Securities also reaffirmed its Buy rating, providing continued support for the company’s longer-term outlook. Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics
• Neutral Sentiment: A recent review highlighted Avalo’s widening losses alongside better-than-expected earnings-per-share trends, raising the possibility that management’s strategic changes could eventually improve performance. However, the company remains unprofitable and the turnaround is not yet established. Do Avalo Therapeutics’ Widening Losses But Better EPS Reveal a Turning Point in Strategy?
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across every listed period. Its FY2026 loss estimate widened to $2.76 per share from $2.02, while its FY2027 loss estimate widened to $2.41 from $1.78. Quarterly estimates for Q3 2026 through Q4 2027 were also reduced, signaling expectations for prolonged cash-burn and weaker profitability. HC Wainwright Cuts Avalo Therapeutics Price Target to $30

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.